聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效观察  

Therapetic effect of pegylated interferon alpha-2a combined with adefovir dipivoxil in the treatment of HBeAg-positive chronic hepatitis B

作　　者：韩思源[1] 荣光[1] 王燕[1] 

机构地区：[1]南方医科大学附属东莞市石龙人民医院,523321

出　　处：《中国实用医药》2014年第20期1-2,共2页China Practical Medicine

摘　　要：目的探讨聚乙二醇干扰素α-2a(Peg-IFNα-2a)联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎(CHB)疗效的观察。方法 147例慢性乙型肝炎患者分为三组,阿德福韦酯组、聚乙二醇干扰素α-2a组及联合组,对比分析在治疗24、36、48周时各组HBV-DNA转阴率、转氨酶复常率、HBeAg转阴率、HBeAg/HBeAb转换率和HBsAg转阴率差别。结果在治疗第24周,联合组患者HBV-DNA下降幅度log(3.56±1.16)明显高于另两组(P<0.05)。在36、48周时,联合组在转氨酶复常率、HBsAg转阴率、HBeAg/HBeAb转换率和HBV-DNA转阴率对比另两组差异有统计意义(P<0.05)。结论聚乙二醇干扰素(Peg-IFNα)联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎优于单一用药。Objective To observe the clinical effect of pegylated interferon alpha-2a（Peg-IFN α-2a） combined with adefovir dipivoxil （ADV） in the treatment of HBeAg-positive CHB.MethodsDivided 147 cases of HBeAg-positive CHB patientsinto three groups： ADV monotherapy group, Peg-IFN α-2a group and combination therapy group. All patients were treated for 48 weeks.The HBsAg negative conversion rates, HBeA/anti-HBe seroconversion rates, the ALT normalization rates and HBV DNA inhibition rates were evaluated on week 24, 36, 48 respectively.ResultsHBV-DNA inhibition rates in combination group was significantly decreased compared with ADV group and Peg-IFN α-2a group at 24th week（P〈0.05）. The HBsAg negative conversion rates, HBeAg/anti-HBe seroconversion rates and HBV DNA inhibition rates in combination group were statistically significant compared with the other two groups（P〈0.05）.ConclusionEfficacy of pegylated interferon α-2a combined with adefovir dipivoxil therapy is superior than monotherapy in the HBeAg-positive CHB.

关 键 词：慢性乙型肝炎 聚乙二醇干扰素Α-2A 阿德福韦酯 

分 类 号：R512.62[医药卫生—内科学]